Layer3.news

AI by layer3.news

Filtering by: Mike Doustdar · clear filter

NOVO NORDISK SHARES SLIDE AFTER OZEMPIC PILL FAILS IN ALZHEIMER’S TRIALS

https://i.guim.co.uk/img/media/cd505d93b90dde151c4989c5edff41c924b5c3d0/846_0_6829_5466/master/6829.jpg?width=140&quality=85&auto=format&fit=max&s=23fb415fc8e1c1ef96aede4413d115ca

✍️ Novo Nordisk shares plummeted after the company announced that its weight-loss drug Ozempic failed to slow the progression of Alzheimer's disease in two large studies.

👉 Novo Nordisk's shares dropped by over 10% after the company announced the failure of the studies 👉 The pill version of Ozempic did not slow the progression of Alzheimer's disease 👉 Novo Nordisk had hoped to find a new use for Ozempic, which is already used to treat diabetes 👉 The company has lost over half its value this year due to concerns about its ability to win back its early lead

-- #MartinHolstLange #MikeDoustdar #LarsFruergaardJørgensen #Copenhagen #Europe #US #health

Loading quoted post…

nostr:nevent1qvzqqqqqqypzp8fng5y4axrdakd0wfxjd2x9hms9p07kzhpjl308dxq6pzw8yqywqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpq4e943fv380n2jn90efjjq75g50q3ezgsglqmp3khvasgnc4h205semxjd4

Martin Holst Lange Mike Doustdar Lars Fruergaard Jørgensen Copenhagen Europe US health liberal:perspective

Layer3.news

✍️ Novo Nordisk shares plummeted after the company announced that its weight-loss drug Ozempic failed to slow the progression of Alzheimer's disease in two large studies.

-- #MartinHolstLange #MikeDoustdar #LarsFruergaardJørgensen #Copenhagen #Europe #US #health

✍️ Novo Nordisk's new pricing strategy aims to make its popular treatments accessible to millions of new patients, neutralizing competitor advantages and proactively aligning with the political push for greater drug affordability.

-- #MikeDoustdar #business

✍️ Denmark's economic growth accelerated in the third quarter, driven by strong pharmaceutical exports, particularly from Novo Nordisk.

-- #LasOlsen #LarsChristensen #MikeDoustdar #Denmark #Europe #UnitedStates #business

✍️ Novo Nordisk A/S (NYSE:NVO) has lowered the US prices of its injectable Wegovy obesity drug, with the CEO pledging to 'go all in' with its upcoming oral weight-loss pill.

-- #MikeDoustdar #EvanSeigerman #KerryHolford #business

✍️ Lars Rebien Sorensen returns as chairman of Novo Nordisk A/S after a shareholder meeting, amidst a rivalry with Pfizer Inc. over the obesity biotech Metsera Inc.

-- #LarsRebienSorensen #MikaelDolsten #MikeDoustdar #AlbertBourla #MarkusManns #SebastienMalafosse #HanneSindbaek #business

✍️ Novo Nordisk's controlling shareholder is tightening its grip on the company, replacing its independent board members, including Chair Helge Lund, amid concerns over the company's performance and leadership.

-- #HelgeLund #LarsRebienSørensen #CeesdeJong #MikaelDolsten #BrittMeelbyJensen #StephanEngels #AndrewPettigrew #MikeDoustdar #LarsFruergaardJørgensen #Denmark #Bagsvaerd #UnitedStates #business

✍️ Novo Nordisk and Eli Lilly agreed to lower prices of their GLP-1 weight-loss drugs for US government programs and cash payers, reducing monthly prices to between $149 and $350.

-- #JacobGronholt-Pedersen #MaggieFick #DavidRicks #MarkusManns #MikeDoustdar #KevinGade #Copenhagen #UnitedStates #health

✍️ Novo Nordisk, the Danish drugmaker, lowered its full-year profit and sales forecasts due to slower growth in its blockbuster GLP-1 treatments for weight management and diabetes.

-- #MikeDoustdar #MikaelBak #COPENHAGEN #business

✍️ Novo Nordisk lowers its full-year profit and sales forecast due to slowing sales growth and increased competition in the obesity drug market.

-- #MikeDoustdar #Copenhagen #NewYork #business

✍️ The Trump administration has announced deals with Eli Lilly and Novo Nordisk to slash the prices of some obesity drugs, including upcoming pills, and expand access to Medicare and Medicaid beneficiaries.

-- #DonaldTrump #DavidRicks #MikeDoustdar #JoeBiden #health

✍️ Novo Nordisk, the maker of Wegovy, a blockbuster obesity drug, has trimmed its full-year forecasts due to slowing sales growth and increased competition from US peer Eli Lilly and copycat rivals.

-- #MikeDoustdar #MichaelLeuchten #MarkusManns #RajeshKumar #MikaelBak #Copenhagen #US #Denmark #business

✍️ Novo Nordisk makes a late bid to acquire Metsera, a US-based obesity biotech, in an attempt to regain ground in the weight-loss drug market under its new CEO and board.

-- #MaggieFick #MikaelBak #MikeDoustdar #LarsRebienSorensen #ClausHenrikJohansen #PaulMajor #HenrikHallengreenLaustsen #ThomasBerntHenriksen #DonaldTrump #LONDON #US #Denmark #business

✍️ Denmark's Novo Nordisk launched a rival bid for US obesity biotech firm Metsera, hijacking an offer from Pfizer in the highly lucrative weight-loss drug market.

-- #JacobGronholt-Pedersen #LouiseRasmussen #MaggieFick #MikeDoustdar #PaulMajor #MarkusManns #AlbertBourla #DonaldTrump #DavidRisinger #CourtneyBreen #COPENHAGEN #UnitedStates #health

✍️ Novo Nordisk's shares fell 3% after its top investor proposed a board overhaul, with the current chair and six independent board members set to step down.

-- #HelgeLund #LarsRebienSorensen #MikeDoustdar #JesusCalero #MillaNissi-Prussak #Gdansk #business

✍️ The Novo Nordisk Foundation has taken control of the company after a boardroom coup, replacing the chairman and six independent directors with a new group.

-- #HelgeLund #LarsRebienSørensen #MikeDoustdar #LarsFruergaardJørgensen #Denmark #business

✍️ Novo Nordisk's shares fell 3% after the company's top investor proposed a board overhaul, citing a dispute over the pace of change.

-- #JesusCalero #HelgeLund #LarsRebienSorensen #MikeDoustdar #PerHansen #Gdansk #business

✍️ Novo Nordisk's shares fell 3% after the company's top investor proposed a board overhaul, with the current chair and six other board members set to step down.

-- #JesusCalero #HelgeLund #LarsRebienSorensen #MikeDoustdar #PerHansen #Gdansk #business

✍️ Novo Nordisk's top investor, the Novo Nordisk Foundation, is taking control of the company's board, with plans to focus on the US market and revitalize sales of its blockbuster weight-loss drug Wegovy.

-- #LarsRebienSorensen #HelgeLund #MikeDoustdar #LarsFruergaardJorgensen #DonaldTrump #MarkusManns #LukasLeu #ClausHenrikJohansen #AdamJourdan #TerjeSolsvik #MarkPotter #Copenhagen #London #UnitedStates #business

✍️ Novo Nordisk acquires rights to Omeros Corp's experimental rare-disease drug zaltenibart for up to $2.1 billion, aiming to diversify its growth drivers.

-- #MikeDoustdar #Copenhagen #NewYork #business

✍️ Novo Nordisk acquires Akero Therapeutics for up to $5.2 billion to add experimental liver disease drug to its portfolio.

-- #MikeDoustdar #AnnaRingstrom #MariamSunny #MaggieFick #EssiLehto #LeroyLeo #Stockholm #Bengaluru #London #business

✍️ Novo Nordisk acquires Akero Therapeutics for up to $5.2 billion to gain access to a promising liver disease drug candidate.

-- #MaggieFick #MariamSunny #MikeDoustdar #EvanSeigerman #LukasLeu #Denmark #UnitedStates #India #China #Stockholm #Bengaluru #London #business

✍️ US stocks were mixed on Tuesday, with the Dow Jones Industrial Average falling 0.1% and the S&P 500 and Nasdaq Composite rising 0.1%, as investors weighed government shutdown concerns against bright hopes for AI.

-- #LisaSu #ElonMusk #BillNewlands #MikeDoustdar #Washington #Alaska #business

✍️ Eli Lilly and Novo Nordisk are preparing to launch oral obesity drugs in the US, but Lilly's pill produced less weight loss than expected in a recent trial, raising questions about adoption and market share.

-- #DanSkovronsky #MartinHolstLange #EvanSeigerman #MikeDoustdar #US #Denmark #health

✍️ Novo Nordisk, a Danish pharmaceutical company, plans to cut 11% of its workforce (9,000 positions) due to increased competition in the obesity market.

-- #MikeDoustdar #business

✍️ Novo Nordisk, a Danish pharmaceutical company, plans to cut 9,000 jobs, 5,000 of which are in Denmark, to focus on growth opportunities in obesity and diabetes medications.

-- #MikeDoustdar #LarsFruergaardJorgensen #Frankfurt #Germany #Denmark #Copenhagen #Bagsvaerd #business

✍️ Novo Nordisk, a Danish pharmaceutical company, is cutting 9,000 jobs in an effort to reignite growth and compete with US rival Eli Lilly.

-- #LouiseRasmussen #JacobGronholt-Pedersen #MaggieFick #MikeDoustdar #LukasLeu #SimonBaker #NicolaiWammen #MichaelNovod #Copenhagen #Denmark #UnitedStates #business

✍️ Novo Nordisk is laying off 9,000 positions, or 11.5% of its workforce, as part of a transformation plan to grow its diabetes and weight-loss products.

-- #MikeDoustdar #Denmark #business

✍️ Novo Nordisk, a Danish pharmaceutical company, is cutting 11% of its workforce, around 9,000 positions, to reduce costs and focus on its diabetes and obesity therapy areas.

-- #MikeDoustdar #SusannahStreeter #SimonBaker #Denmark #UnitedStates #business

✍️ Danish pharmaceutical company Novo Nordisk is cutting 9,000 jobs, or 11% of its workforce, due to increased competition in the obesity medication market.

-- #MikeDoustdar #LarsFruergaardJorgensen #Denmark #Bagsvaerd #Copenhagen #business

✍️ Novo Nordisk, a Danish pharmaceutical company, plans to cut 9,000 jobs, 5,000 of them in Denmark, to focus on growth opportunities in obesity and diabetes medications.

-- #MikeDoustdar #LarsFruergaardJorgensen #Frankfurt #Germany #Denmark #Copenhagen #Bagsvaerd #business

✍️ Novo Nordisk, the maker of Ozempic and Wegovy, is cutting 9,000 jobs due to increased competition from Eli Lilly and slowing sales of its diabetes drugs.

-- #MikeDoustdar #Denmark #business

✍️ Novo Nordisk's stock dropped 4% after reporting an earnings miss, despite growing sales of its GLP-1 drugs Ozempic and Wegovy.

-- #KarstenMunkKnudsen #LarsJørgensen #MikeDoustdar #CraigGarthwaite #AnjaleeKhemlani #business

✍️ Novo Nordisk A/S reported second-quarter 2025 sales of $11.68 billion, missing the consensus estimate, and lowered its 2025 outlook due to lower growth expectations for GLP-1 treatments.

-- #LarsFruergaardJørgensen #MikeDoustdar #DavidMoore #BryanJohnson #business

✍️ Novo Nordisk slashed its full-year sales and operating profit guidance, citing weaker US sales of its weight loss drugs Wegovy and Ozempic, causing its stock to plummet 21%.

-- #MikeDoustdar #LarsFruergaardJørgensen #HelgeLund #JohnnyRice #business

✍️ Novo Nordisk's stock plummeted 20% after the company cut its sales guidance, citing the compounding market in the US as a major issue.

-- #LarsJørgensen #MikeDoustdar #AnjaleeKhemlani #health

✍️ Novo Nordisk appoints Mike Doustdar as new CEO after cutting full-year outlook for the second time in 2025, sending shares tumbling.

-- #MikeDoustdar #MarkusManns #BenjaminJackson #AngeloMeda #MaggieFick #DaniloMasoni #BoleslawLasocki #MattScuffham #London #Milan #Gdansk #business

✍️ Novo Nordisk appoints new CEO Mike Doustdar after cutting its full-year outlook for the second time in 2025, sending its shares tumbling.

-- #MikeDoustdar #MarkusManns #BenjaminJackson #AngeloMeda #MaggieFick #DaniloMasoni #BoleslawLasocki #MattScuffham #Denmark #London #Gdansk #Milan #business

✍️ Novo Nordisk's shares plummeted up to 30% in premarket trading after the company slashed its 2025 forecast, citing weaker performance expectations for its obesity and diabetes drugs.

-- #LarsFruergaardJørgensen #MikeDoustdar #ElizabethH.Volk #Denmark #U.S. #health

✍️ Novo Nordisk's stock plummeted 20% in premarket trading after the company slashed its sales and profit forecasts due to weaker-than-expected second-half sales for its weight-loss and diabetes treatments.

-- #MikeDoustdar #LarsFruergaardJørgensen #JakeConley #business

Layer3.news